Press Releases

280Bio doses first patient in Phase I clinical trial of TEB-17231, an oral pan-RAS inhibitor in patients with advanced cancers harboring mutations in KRAS, HRAS, or NRAS

12/07/2023

Excerpt from the Press Release: SOUTH SAN FRANCISCO, Calif., Dec. 1, 2023 /PRNewswire/ — 280Bio, Inc., a clinical stage biotechnology company focused on the development of precision oncology medicines, today announced that the first patient was treated with TEB-17231 (YL-17231), a small molecule inhibitor of RAS signaling. 280Bio is a wholly owned subsidiary of Shanghai…

Read More

Neurona Therapeutics Presents New Clinical Data from First Cohort in Ongoing Phase I/II Open-Label Trial of NRTX-1001 Cell Therapy for Drug-resistant Mesial Temporal Lobe Epilepsy (MTLE)

12/06/2023

NRTX-1001 investigational treatment has been well tolerated in all initial subjects Positive decision from data safety monitoring board (DSMB) on review of first cohort safety data greenlights dosing of five additional subjects in the second, highest dose, cohort First two subjects continue to report a >95% reduction in overall average monthly seizure counts one year…

Read More

Bioxodes Closes €12 million in Series A Funding Round

12/05/2023

Excerpt from the Press Release: Bioxodes SA has received €12 million ($13M) in a Series A funding from historic investors. This financial backing includes €8.6 million ($9.3M) in capital and €3.4 million ($3.7M) in non-dilutive funding from the Wallonia region. It comes on top of the €27 million ($29.2M) in capital and subsidies previously raised by Bioxodes, bringing to €39 million ($42.2M)…

Read More

GSK Blood Cancer Drug Blenrep Hits Goal in Late-Stage Trial

12/04/2023

Excerpt from the Press Release: The trial met its primary endpoint of progression-free survival (PFS) and showed that belantamab mafodotin when combined with bortezomib plus dexamethasone (BorDex) significantly extended the time to disease progression or death versus daratumumab plus BorDex, an existing standard of care for relapsed/refractory multiple myeloma. A strong and clinically meaningful overall…

Read More

1nhaler Raises £2 Million to Develop Single-Use Sustainable Inhaler

12/01/2023

Excerpt from the Press Release: Inhalable medicines are already widely used to treat conditions such as asthma, epilepsy, allergies and Parkinson’s but, to date, delivery options have been limited due to user accessibility, cost, performance and impact on the environment. 1nhaler has developed a way of enabling many different dry powder drugs to be readily…

Read More

NeuroOne Picks Up Patent for Drug Delivery Device

11/30/2023

Excerpt from the Press Release: NeuroOne Medical Technologies Corporation have announced that the United States Patent and Trademark Office issued a Notice of Allowance for U.S. Patent Application 16/812,702, titled “Agent-Delivering Neural Probe Devices and Related Systems and Methods,” which covers novel electrodes that can operate as a standard neural electrode that also delivers a treatment agent to…

Read More

BIOVECTRA Launches Specialized Capabilities in mRNA Drug Product Development and Biomanufacturing

11/29/2023

Excerpt from the Press Release: “This expansion places BIOVECTRA at the forefront of supporting the next generation of treatments for today’s rare and incurable diseases and producing vaccines to tackle future pandemics,” said BIOVECTRA CEO Oliver Technow. “Today also marks a milestone in the accelerated growth of Atlantic Canada’s bioscience sector and celebrates the creation…

Read More

Fusion Pharmaceuticals Strengthens Actinium Supply with Onsite Isotope Production through Expanded BWXT Medical Collaboration

11/24/2023

Excerpt from the Press Release: HAMILTON, ON and BOSTON, Nov. 16, 2023 /PRNewswire/ — Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), and BWXT Medical Ltd., a subsidiary of BWX Technologies, Inc. (NYSE: BWXT), today announced that the companies have entered into a new agreement for the supply of generators to produce actinium-225, a medical isotope used to treat cancer in clinical trials. Under…

Read More

BPGbio Announces Phase 2 BPM31510 Glioblastoma Trial-in-Progress Update at Society for Neuro-Oncology Annual Meeting

11/23/2023

Excerpt from the Press Release: BOSTON–(BUSINESS WIRE)–BPGbio, Inc., a leading biology-first AI-powered biopharma that focuses on oncology, neurology, and rare diseases, today announced that researchers will present data from an ongoing phase 2 trial study of BPGbio lead candidate, BPM31510, in patients with newly diagnosed glioblastoma multiforme (GBM), at the Society for Neuro-Oncology Annual Meeting…

Read More

World-first gene therapy for 2 blood disorders — sickle cell and thalassemia — approved

11/22/2023

Casgevy the 1st medicine licensed using the gene editing tool CRISPR Excerpt from the Press Release: Britain’s medicines regulator has authorized the world’s first gene therapy treatment for sickle cell disease, in a move that could offer relief to thousands of people with the disease in the U.K.  In a statement on Thursday, the Medicines…

Read More